Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Christoph Kornauth, Tea Pemovska, PhDMSc,BSc, Gregory Ian Vladimer, PhD, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, Harald Esterbauer, MD PhD, Ruth Exner, Verena Felsleitner-Hauer, Maurizio Forte, MSc, Alexander Gaiger, Hildegard T. Greinix, MD, Wolfgang Gstöttner, Marcus Hacker, Alexander Hauswirth, MD, Tim Heinemann, Daniel Heintel, Mir Ali Reza Hoda, Ulrich Jaeger, Lukas Kazianka, MD, Lukas Kenner, MD, Barbara Kiesewetter, MD, Nikolaus Krall, PhD, Trang Le, BSc, Simone Lubowitzki, Marius E Mayerhoefer, Elisabeth Menschel, Olaf Merkel, PhD, Katsuhiro Miura, MD PhD, Leonhard Muellauer, MD PhD, Peter Neumeister, MD, Thomas Noesslinger, MD, Katharina Ocko, Leopold Öhler, Michael Panny, MD, Alexander Pichler, MD, Edit Anna Porpaczy, MD, Gerald Prager, MD, Markus Raderer, Robin Ristl, Reinhard Ruckser, MD, Julius Salamon, Ana-Iris Schiefer, Ann-Sofie Schmolke, MD, Ilse Schwarzinger, MD, Edgar Selzer, Cathrin Skrabs, Wolfgang R. Sperr, MD, Ismet Srndic, MSc, Renate Thalhammer, MD, Peter Valent, MD, Emiel van der Kouwe, PharmD, Katrina Vanura, PhD, Stefan Vogt, Cora Waldstein, Dominik Wolf, Univ. Prof. Dr., Christoph Zielinski, Ingrid Simonitsch-Klupp, MD, Giulio Superti-Furga, PhD, Berend Snijder, PhD, Philipp B. Staber, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140831

Published: 2020

Journal Articles

Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients

Felix Keil, MD, Lisa Obenaus, BSc, Victor Rathkolb, MD, Michael Leiner, MD, Robert Spörk, MSc, Elisabeth Koller, MD, Ernst Forjan, MD, Ralph Simanek, MD, Michael Panny, MD, Daniel Lechner, MD, Alexandra Böhm, MD, Anabel Schönmetzler, MD, Theresia Kornberger, MD, Thomas Noesslinger, MD

Blood (2019) 134 (Supplement_1): 5458.

https://doi.org/10.1182/blood-2019-122024

Published: 2019

Journal Articles

Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Thomas Noesslinger, MD, Michael Panny, MD, Michaela Moestl, MD, Elisabeth Koller, MD, Felix Keil, MD

Blood (2016) 128 (22): 2265.

https://doi.org/10.1182/blood.V128.22.2265.2265

Published: 2016

Journal Articles

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Blood (2016) 128 (22): 229.

https://doi.org/10.1182/blood.V128.22.229.229

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Thomas Noesslinger, MD, Michaela Moestl, MD, Christoph Tinchon, MD, Elisabeth Koller, MD, Werner Linkesch, Univ. Prof, MD, Felix Keil, MD

Blood (2014) 124 (21): 3982.

https://doi.org/10.1182/blood.V124.21.3982.3982

Published: 2014

Journal Articles

Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)

Blood (2014) 124 (21): 4699.

https://doi.org/10.1182/blood.V124.21.4699.4699

Published: 2014

Journal Articles

Hypermethylation and Reduced Carnitine Availability - Possible Mechanisms for Downregulation of Microsomal Carnitine Palmitoyltransferase (mCPT) in Myelodysplastic Syndromes (MDS).

Michael Pfeilstocker, MD, Heidrun Karlic, PhD, Peter Wihlidal, Thomas Noesslinger, MD, Elisabeth Pittermann, MD

Blood (2006) 108 (11): 2648.

https://doi.org/10.1182/blood.V108.11.2648.2648

Published: 2006

Journal Articles

Individualizing IPSS Risk Assessment in Myelodysplastic Syndromes, by Additionally Taking into Account Age, Gender and French-American-British (FAB) Classification - A Multicenter Analysis.

Thomas Noesslinger, MD, Heinz Tuechler, Ulrich Germing, MD, Peter Valent, Otto Krieger, MD, Detlev Haase, MD, Reinhard Stauder, Michael Pfeilstocker

Blood (2006) 108 (11): 2618.

https://doi.org/10.1182/blood.V108.11.2618.2618

Published: 2006

Journal Articles

New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.

Detlef Haase, MD, PhD, Ulrich Germing, MD, PhD, Julie Schanz, MD, Michael Pfeilstoecker, MD, PhD, Thomas Noesslinger, MD, Barbara Hildebrandt, PhD, Andrea Kuendgen, MD, Michael Luebbert, MD, PhD, Aristoteles Giagounidis, MD, Carlo Aul, MD, PhD, Lorenz Truemper, MD, PhD, Thomas Mueller, PhD, Peter Valent, MD PhD, Christa Fonatsch, MD, PhD, Christian Steidl, MD

Blood (2006) 108 (11): 248.

https://doi.org/10.1182/blood.V108.11.248.248

Published: 2006

Journal Articles

Sequential Cytogenetic Analyses of 577 Patients with Myelodysplastic Syndromes: Correlations between Initial Karyotype, Cytogenetic Dynamics, and Clinical Course.

Christian Steidl, MD, Rainer Schabla, MD, Ulrich Germing, MD, PhD, Barbara Hildebrandt, PhD, Thomas Noesslinger, MD, Michael Pfeilstoecker, MD, PhD, Aristoteles Giagounidis, MD, PhD, Regina Kunzmann, PhD, Peter Haas, MD, Michael Luebbert, MD, PhD, Lorenz Truemper, MD, PhD, Detlef Haase, MD, PhD

Blood (2005) 106 (11): 2531.

https://doi.org/10.1182/blood.V106.11.2531.2531

Published: 2005

Journal Articles

Excellent Stem Cell Mobilization Using Escalated BEACOPP in High-Risk Patients with Hodgkin’s Disease.

Gabriele Kandler, MD, Michael Fillitz, MD, Michaela Moestl, MD, Ernst Schloegl, MD, Regina Reisner, MD, Elisabeth Pittermann-Hoecker, MD, Thomas Noesslinger, MD, Michael Pfeilstoecker, MD Univ.Doz

Blood (2005) 106 (11): 4717.

https://doi.org/10.1182/blood.V106.11.4717.4717

Published: 2005

Journal Articles

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Johannes Drach, MD, Jutta Ackermann, Catrin Baldia, MD, Hannes Kaufmann, MD, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Sonja Seidl, MD, Verena Sagaster, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ulrich Jaeger, MD, Christoph Zielinski, MD

Blood (2004) 104 (11): 4873.

https://doi.org/10.1182/blood.V104.11.4873.4873

Published: 2004

Journal Articles

Sequential Cytogenetic Analysis of 322 Patients with Myelodysplastic Syndromes. Delineation of Genetic Evolution and Clinical Implications.

Christian Steidl, MD, Rainer Schabla, Ulrich Germing, MD, PhD, Barbara Hildebrandt, MD, Thomas Noesslinger, MD, Michael Pfeilstocker, MD, PhD, Peter Haas, MD, Michael Lübbert, MD, PhD, Lorenz H. Truemper, MD, PhD, Detlef Haase, MD, PhD

Blood (2004) 104 (11): 2368.

https://doi.org/10.1182/blood.V104.11.2368.2368

Published: 2004

Journal Articles

The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.

Thomas Noesslinger, MD, Ulrich Germing, MD, PD, Barbara Hildebrandt, MD, Claudia Strupp, MD, Manuel Aivado, MD, Detlef Haase, MD, Julie Schanz, MD, Friedrich Wimazal, MD, Wolfgang Sperr, MD, Valent Peter, MD, Lubbert Michael, MD, PD, Otto Krieger, MD, Norbert Gattermann, MD, Aristoteles Giagounidis, MD, Heinz Tuchler, Rainer Haas, MD, Carlo Aul, MD, Michael Pfeilstocker, MD, PD

Blood (2004) 104 (11): 1448.

https://doi.org/10.1182/blood.V104.11.1448.1448

Published: 2004

Journal Articles

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Hannes Kaufmann, MD, Catrin Baldia, MD, Jutta Ackermann, Thomas Noesslinger, MD, Heinz Gisslinger, MD, Ulrich Jaeger, MD, Verena Sagaster, MD, Sonja Seidl, MD, Andrea Keck, MD, Heinz Ludwig, MD, Ingrid Simonitsch-Klupp, MD, Christoph Zielinski, MD, Johannes Drach, MD

Blood (2004) 104 (11): 3459.

https://doi.org/10.1182/blood.V104.11.3459.3459

Published: 2004

NARROW

Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Long-Time Follow-up of 888 Patients Diagnosed with CLL on a Single Center: Comorbidities, Time-to-Treatment and Comparison between Treated and Untreated Patients

Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)

Autologous Stem Cell Transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma

Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)

Hypermethylation and Reduced Carnitine Availability - Possible Mechanisms for Downregulation of Microsomal Carnitine Palmitoyltransferase (mCPT) in Myelodysplastic Syndromes (MDS).

Individualizing IPSS Risk Assessment in Myelodysplastic Syndromes, by Additionally Taking into Account Age, Gender and French-American-British (FAB) Classification - A Multicenter Analysis.

New and Comprehensive Cytogenetic Prognostication and Categorization in MDS.

Sequential Cytogenetic Analyses of 577 Patients with Myelodysplastic Syndromes: Correlations between Initial Karyotype, Cytogenetic Dynamics, and Clinical Course.

Excellent Stem Cell Mobilization Using Escalated BEACOPP in High-Risk Patients with Hodgkin’s Disease.

The Chromosomal Pattern 14q-Translocation Plus 13q-Deletion Is Characteristic for Multiple Myeloma after a Preceding Monoclonal Gammopathy of Undetermined Significance.

Sequential Cytogenetic Analysis of 322 Patients with Myelodysplastic Syndromes. Delineation of Genetic Evolution and Clinical Implications.

The Influence of Age and Gender on the Prognostic Impact of Karytoypic Subgroups in Myelodysplastic Syndromes - a Multicenter Analysis.

Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only